

Reducing Surgical Site Infection After Caesarean Section : Effectiveness of Leukomed Sorbact Dressing !

To reduce **surgical site infections** (SSIs) after caesarean sections, the UHB NHS Maternity Unit adopted **Leukomed® Sorbact®** dressings on February 5th, 2024, as per NICE guidance¹. These sterile dressings use DACC (Di-alkyl carbamoyl chloride) that binds to hydrophobic bacteria, promoting faster healing, and reducing complications & costs associated with SSIs.

Authors:

- Dr. Kritika Vats (JSD higher)
- Dr. Sagarika Dubey (JSD)
- Dr Anam Ghafoor (ITF)
- Dr. Charu Gupta (Consultant Obstetrics and Gynaecology)




**University Hospitals
Birmingham**
NHS Foundation Trust



AIM

- To compare Post-Caesarean **SSI and Readmission Rates** before and after introduction of Leukomed Sorbact.
- Determine any **resource savings** from the use of Leukomed Sorbact.
- To make **recommendations** for further improvement



METHODOLOGY

Data Collection

Patients visiting
Maternity triage
With surgical site
infections

Time Period


3 months before
& after implementing
Leukomed® Sorbact®
(01.Nov.23 -
31.Apr.24)

Analysis

Data
compared &
analysed on
MS Excel


Note: Cases with Deep SSI and incomplete documentation were excluded.

36% Reduction in SSI Rates after using Leukomed Sorbact




RESULTS


50% Reduction in SSI Antibiotic Prescriptions



38% Decline in patients re-admitted due to SSI




Surgical Site Infection Rates by Body Mass Index



Conclusion & Recommendations

By reducing SSI after C-sections, Leukomed Sorbact dressings have shown to decrease readmissions, antibiotic use, and wound complications. This is particularly effective for patients with high BMI. Surgical site infections are a persistent major problem despite better antibiotics and wound care, demanding a multi-pronged prevention strategy.² This includes patient optimization, improved peri-surgical practices, and adherence to NICE guidelines. Early detection and treatment are vital to minimize impact.



References

- 1) National Institute for Health and Care Excellence. NICE medical technology guidance 55 (2021),
- 2) Surgical site infection in obstetrics and gynaecology: prevention and management, TOG (2021)